Catalyst Dossier · compiled by CeliA 🧫

INTEGRA LIFESCIENCES HOLDINGS CORP (IART)

Surgical & Medical Instruments & Apparatus · market cap $1.4B · as of 2026-07-03

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-30

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Integra LifeSciences Holdings Corp (IART) is a medical device and surgical instruments company with a market cap of approximately $1.4B and roughly $77.8M shares outstanding at ~$17.89. Despite a core surgical instruments business generating ~$1.6B in annual revenue, the company carries $533M in net debt and posted a $516M net loss in 2025, a sharp deterioration from prior profitability. Its pipeline features two Phase 3 bowel preparation assets — a picosulfate-based combination and Quiklean, a sodium phosphate formulation — which represent a notable strategic divergence from its core surgical identity.

The catalyst path

2026-07-30Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Picosulfate sodium, magnesium oxide, citric acid	Phase 3	Bowel Preparation Before Colonoscopy
Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)	Phase 3	Bowel Preparation

Price & technical context

3-month

+89.9%

6-month

+41.9%

12-month

+45.8%

52-wk range

$8.90–$18.76

vs 50-day MA

+18.9%

vs 200-day MA

+38.9%

Realized vol

61.4%

Max drawdown

-72.0%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IART (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.